The drug maker's scrip climbed 4.32 per cent to Rs 787.05 at BSE.
On NSE, the scrip went up 4.31 per cent to Rs 787.
The firm had posted a net profit of Rs 403.8 crore in the January-March period of 2014-15 fiscal.
Net sales of the company rose to Rs 3,674.7 crore in the fourth quarter of 2015-16 fiscal. It had reported a net sales of Rs 3,143.97 crore during the same period of the previous fiscal, Aurobindo Pharma had said in a regulatory filing yesterday.
Net sales of the company stood at Rs 13,650.61 crore in the 2015-16 fiscal, while it was Rs 12,043.23 crore in the preceding fiscal.
The company said results of the quarter and year ended March 31, were not comparable with those of previous year.
The company's board had approved interim dividend of 70 per cent, Re 0.70 per equity share of Re 1 each on the equity share capital of the company for the year 2015-16.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
